Opinion|Videos|May 13, 2024

Monitoring Patients with Relapsed/Refractory Multiple Myeloma

Author(s)Rahul Gosain, MD, Rohit Gosain, MD, Samer A. Al'Hadidi, MD

Samer Al'Hadidi, MD, discusses monitoring strategies for patients with relapsed/refractory multiple myeloma who are receiving lenalidomide.

Episodes in this series

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

EP. 1 Monitoring Patients with Relapsed/Refractory Multiple Myeloma

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

EP. 2 The Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

EP. 3 Adverse Effect Management for CAR T-Cell Therapy and Bispecifics in R/R MM

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

EP. 4 Treatment Decision-Making in Relapsed/Refractory Multiple Myeloma

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

EP. 5 Advice for Community Oncologists Treating R/R Multiple Myeloma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

September 18th, 2026

NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

Treatment Strategies in Multiple Myeloma are Changing: © stock_acc - stock.adobe.com

September 12th, 2026

Debating CAR T-Cell Therapy Vs Bispecifics at First Relapse in Myeloma

Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.

Trending on CancerNetwork

Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026

CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma

FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer

Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC

NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma